
CLAIMS

1. Use of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)acetamide for the manufacture of a medicament for the treatment of an autoimmune disorder in a subject, wherein the autoimmune disorder is chronic graft-versus-host disease (cGVHD), acute GVHD (aGVHD), pulmonary fibrosis, idiopathic pulmonary fibrosis, moderate to severe psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), Crohn's disease, atopic dermatitis or eczema.


2. The use according to claim 1, wherein the autoimmune disorder is chronic GVHD (cGVHD).

3. An isolated or synthesized compound comprising belumosudil glucuronide, O-dealkylated belumosudil sulfate, monohydroxy belumosudil, or belumosudil diol, or a pharmaceutically-acceptable salt thereof.


4. The compound according to claim 3, having the formula:




glucuronide ;




;



;




; or



,

wherein —— represents a single bond that links any available carbon atom within the bracketed portion of the molecule to the moiety or moieties adjacent to said brackets; or a pharmaceutically-acceptable salt thereof.

5. The isolated compound according to claim 4, that is belumosudil glucuronide having the formula:




, or

a pharmaceutically acceptable salt thereof.

6. The isolated compound according to claim 5, characterized in that it has a molecular weight of 628.


7. The isolated compound according to claim 4, that is O-dealkylated belumosudil sulfate, having the formula:




, or a pharmaceutically acceptable salt thereof.

8. The isolated compound according to claim 7, characterized in that it has a molecular weight of 433.

9. The isolated compound according to claim 4, that is monohydroxy belumosudil having the formula:



; or




,

or a pharmaceutically acceptable salt thereof.

10. The isolated compound according to claim 9, characterized in that it has a molecular weight of 468.

11. The isolated compound according to claim 4, that is belumosudil diol having the formula:



, or a pharmaceutically acceptable salt thereof.

12. The isolated compound according to claim 11, characterized in that it has a molecular weight of 486.

13. The isolated compound according to any one of claims 3 to 12, characterized in that it has a molecular weight or retention time as shown in Table 3, or a pharmaceutically acceptable salt thereof.

14. Use of a compound according to any one of claims 3 to 12, in the manufacture of a medicament for the treatment of an autoimmune disease in a subject.

15. The use according to claim 14, wherein the autoimmune disease is chronic GVHD (cGVHD).

16. A pharmaceutical composition comprising a compound according to any one of claims 3 to 12, and a pharmaceutically acceptable carrier.

17. Use of a compound according to any one of claims 3 to 12, or of a pharmaceutical composition according to claim 16, in the manufacture of a medicament for the treatment of an autoimmune disorder in a subject wherein the autoimmune disorder is chronic GVHD (cGVHD), acute GVHD (aGVHD), pulmonary fibrosis, idiopathic pulmonary fibrosis, moderate to severe psoriasis, rheumatoid arthritis, multiple

sclerosis, systemic lupus erythematosus (SLE), Crohn's disease, atopic dermatitis or eczema.

18. The use according to claim 17, wherein the autoimmune disorder is pulmonary fibrosis or chronic GVHD (cGVHD).

19. Use of a compound according to any one of claims 3 to 12, or the metabolic pathway for belumosudil, in the preparation of a medicament for the treatment of an autoimmune disease in a subject.

20. Use of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)acetamide or 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)acetic acid, for the manufacture of a medicament for the treatment of an autoimmune disorder in a subject.

21. The use according to claim 3 to 20,

(a) wherein the medicament is prepared in a unit dosage for administration of an active pharmaceutical agent to a subject taking into consideration drug-drug interactions; and/or
(b) wherein the medicament contains a combination of active pharmaceutical agents to be administered to the subject; and/or
(c) wherein the active pharmaceutical agent is 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)acetamide.